Skip to main content

Table 1 Baseline characteristics of patients

From: Preexisting respiratory diseases and clinical outcomes in COVID-19: a multihospital cohort study on predominantly African American population

Characteristics Cohort (n = 1871)
Age, n (%)
 Mean (SD) 64.11 (16)
  < 65 874 (46.7)
  ≥ 65 997 (53.3)
Sex, n (%)
 Male 965 (51.6)
 Female 906 (48.4)
Race/ethnicity, n (%)
 African American 1494 (79.9)
 White 340 (18.2)
 Asian 21 (1.1)
 Middle Eastern 14 (0.7)
 Latino/Hispanic 2 (0.1)
BMI, mean (SD) 31.14 (8.82)
  < 18.5 (underweight) 46 (2.5)
 18.5–24.9 (normal) 411 (22)
 25–29.9 (overweight) 512 (27.4)
  ≥ 30 (obese) 897 (47)
Preexisting respiratory disease, n (%) 575 (30.7)
 COPD 317 (16.9)
 Asthma 134 (7.2)
 Obstructive sleep apnea 63 (3.4)
 Pulmonary embolism 27 (1.4)
Pulmonary hypertension 10 (0.5)
 Sarcoidosis 8 (0.4)
 Lung cancer 9 (0.5)
 Prior TB/ILD 5 (0.3)
Number of comorbidities, n (%)  
 0 257 (13.7)
 1 362 (19.3)
 2 443 (23.7)
  ≥ 3 809 (43.2)
Current or former smoker, n (%) 704 (37.6)
Individual preexisting respiratory disease severity
 COPD, n (%) 317
 GOLD grade I 40 (12.6)
 GOLD grade II 18 (5.7)
 GOLD grade III 16 (5)
 GOLD grade IV 5 (1.6)
 Cannot be determined 238 (75.1)
Asthma, n (%) 134
 Intermittent 9 (6.7)
 Mild 13 (9.7)
 Moderate 5 (3.7)
 Severe 2 (1.5)
 Cannot be determined 105 (78.4)
Obstructive sleep apnea, n (%) 63
 Mild (5 ≤ AHI < 15) 7 (11.1)
 Moderate (15 ≤ AHI < 30) 6 (9.5)
 Severe (AHI ≥ 30) 18 (28.6)
 Cannot be determined 32 (50.8)
Pulmonary Hypertension (based on mPAP), n (%) 10
 Mid 4 (40)
 Moderate 1 (10)
 Severe 2 (20)
 Cannot be determined 3 (30)
Sarcoidosis, n (%) 8
 Stage 0 3 (37.5)
 Stage 1 2 (25)
 Cannot be determined 3 (37.5)
  1. SD Standard deviation, AHI Apnea–hypopnea index, mPAP Mean pulmonary arterial pressure
  2. mPAP Mean pulmonary arterial pressure
\